Phase I Trial of PACE for Metastatic Prostate Cancer
Status:
Withdrawn
Trial end date:
2019-12-18
Target enrollment:
Participant gender:
Summary
This trial is being conducted to determine the feasibility and recommended dose of the
combination of four drugs (prednisone, abiraterone, cabazitaxel and enzalutamide (PACE) as
first-line therapy for metastatic castration-resistant prostate cancer (mCRPC).